{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:43:31Z","timestamp":1793043811682,"version":"4.5.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myelofibrosis (MF) is a clonal hematopoietic stem cell neoplasm characterized by constitutional symptoms, splenomegaly, and risks of marrow failure or leukemic transformation and is universally driven by Jak\/STAT pathway activation. Despite sharing this pathogenic feature, MF disease behavior can vary widely. MF can generally be categorized into 2 distinct subgroups based on clinical phenotype: proliferative MF and cytopenic (myelodepletive) MF. Compared to proliferative phenotypes, cytopenic MF is characterized by lower blood counts (specifically anemia and thrombocytopenia), more frequent additional somatic mutations outside the Jak\/STAT pathway, and a worse prognosis. Cytopenic MF presents unique therapeutic challenges. The first approved Jak inhibitors, ruxolitinib and fedratinib, can both improve constitutional symptoms and splenomegaly but carry on-target risks of worsening anemia and thrombocytopenia, limiting their use in patients with cytopenic MF. Supportive care measures that aim to improve anemia or thrombocytopenia are often ineffective. Fortunately, new treatment strategies for cytopenic MF are on the horizon. Pacritinib, selective Jak2 inhibitor, was approved in 2022 to treat patients with symptomatic MF and a platelet count lower than 50\u200a\u00d7\u200a109\/L. Several other Jak inhibitors are in development to extend therapeutic benefits to those with either anemia or thrombocytopenia. While many other novel non\u2013Jak inhibitor therapies are in development for MF, most carry a risk of hematologic toxicities and often exclude patients with baseline thrombocytopenia. As a result, significant unmet needs remain for cytopenic MF. Here, we discuss clinical implications of the cytopenic MF phenotype and present existing and future strategies to tackle this challenging disease.<\/jats:p>","DOI":"10.1182\/hematology.2022000340","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:09:27Z","timestamp":1670602167000},"page":"235-244","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["New approaches to tackle cytopenic myelofibrosis"],"prefix":"10.1182","volume":"2022","author":[{"given":"Samuel B.","family":"Reynolds","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Pettit","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"17","key":"2022121313285875600_hem2022000340C1","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2022121313285875600_hem2022000340C2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.6004\/jnccn.2020.7557","article-title":"A practical guide for using myelofibrosis prognostic models in the clinic","volume":"18","author":"How","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2022121313285875600_hem2022000340C3","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2022121313285875600_hem2022000340C4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/2040620712459746","article-title":"Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians","volume":"3","author":"Harrison","year":"2012","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"2022121313285875600_hem2022000340C5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","article-title":"The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication","volume":"20","author":"Marcellino","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2022121313285875600_hem2022000340C6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2022121313285875600_hem2022000340C7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"issue":"April","key":"2022121313285875600_hem2022000340C8","doi-asserted-by":"crossref","first-page":"106338","DOI":"10.1016\/j.leukres.2020.106338","article-title":"Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported","volume":"91","author":"Masarova","year":"2020","journal-title":"Leuk Res"},{"issue":"suppl 15","key":"2022121313285875600_hem2022000340C9","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/JCO.2016.34.15_suppl.7068","article-title":"Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count &lt;50\u200a\u00d7\u200a109\/L: a single-center experience in 1100 myelofibrosis patients","volume":"34","author":"Alhuraiji","year":"2016","journal-title":"Am Soc Clin Oncol"},{"issue":"5","key":"2022121313285875600_hem2022000340C10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2022121313285875600_hem2022000340C11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Hern\u00e1ndez-Boluda","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"2022121313285875600_hem2022000340C12","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2022121313285875600_hem2022000340C13","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden \u226550% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2022121313285875600_hem2022000340C14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2022121313285875600_hem2022000340C15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2022121313285875600_hem2022000340C16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2022121313285875600_hem2022000340C17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clml.2021.10.016","article-title":"Safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts (50-100\u202f\u200a\u00d7\u200a\u202f109\/L): final analysis of an open-label phase 2 study","volume":"22","author":"Talpaz","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2022121313285875600_hem2022000340C18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br J Haematol"},{"issue":"5","key":"2022121313285875600_hem2022000340C19","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3324\/haematol.2018.204602","article-title":"EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis","volume":"104","author":"Vannucchi","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"2022121313285875600_hem2022000340C20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/leu.2013.205","article-title":"Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)","volume":"28","author":"Zhou","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2022121313285875600_hem2022000340C21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"7","key":"2022121313285875600_hem2022000340C22","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"2022121313285875600_hem2022000340C23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"2022121313285875600_hem2022000340C24","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1124\/dmd.114.058883","article-title":"The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy","volume":"42","author":"Zhang","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"2022121313285875600_hem2022000340C25","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts [published online ahead of print 27 April 2020]","author":"Harrison","journal-title":"Br J Haematol"},{"issue":"16 August","key":"2022121313285875600_hem2022000340C26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J Exp Pharmacol"},{"issue":"5","key":"2022121313285875600_hem2022000340C27","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2022121313285875600_hem2022000340C28","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"22","key":"2022121313285875600_hem2022000340C29","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"2022121313285875600_hem2022000340C30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2022121313285875600_hem2022000340C31","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"issue":"34","key":"2022121313285875600_hem2022000340C32","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022121313285875600_hem2022000340C33","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"suppl 16","key":"2022121313285875600_hem2022000340C34","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1200\/JCO.2022.40.16_suppl.7002","article-title":"MOMENTUM: phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor","volume":"40","author":"Mesa","year":"2022","journal-title":"J Clin Oncol"},{"key":"2022121313285875600_hem2022000340C35","unstructured":"National Center for Biotechnology Information. PubChem compound summary for CID 46866319, ilginatinib. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ilginatinib. Accessed 1July2022."},{"issue":"2","key":"2022121313285875600_hem2022000340C36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/leu.2016.215","article-title":"A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis","volume":"31","author":"Verstovsek","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"2022121313285875600_hem2022000340C37","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V128.22.1936.1936","article-title":"Phase 1\/2 study of NS-018, an oral JAK2 inhibitor, in patients with primary myelofibrosis (PMF), post- polycythemia vera myelofibrosis (postPV MF), or post-essential thrombocythemia myelofibrosis (postET MF)","volume":"128","author":"Verstovsek","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2022121313285875600_hem2022000340C38","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2022121313285875600_hem2022000340C39","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/MCB.01365-08","article-title":"BRD4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA","volume":"29","author":"Huang","year":"2009","journal-title":"Mol Cell Biol"},{"issue":"suppl 1","key":"2022121313285875600_hem2022000340C40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2021-150172","article-title":"Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis\u2014update of clinical and translational data from the ongoing manifest trial","volume":"138","author":"Kremyanskaya","year":"2021","journal-title":"Blood"},{"issue":"S3","key":"2022121313285875600_hem2022000340C41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.HS9.0000843684.97625.7e","article-title":"S198: BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis\u2014Jak inhibitor na\u00efve or with suboptimal response to ruxolitinib\u2014preliminary data from the MANIFEST study","volume":"6","author":"Mascarenhas","year":"2022","journal-title":"HemaSphere"},{"issue":"4","key":"2022121313285875600_hem2022000340C42","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"issue":"15","key":"2022121313285875600_hem2022000340C43","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1200\/JCO.21.02188","article-title":"Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy","volume":"40","author":"Harrison","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313285875600_hem2022000340C44","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol"},{"issue":"6","key":"2022121313285875600_hem2022000340C45","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1182\/blood.V91.6.1917","article-title":"The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis","volume":"91","author":"Bruno","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2022121313285875600_hem2022000340C46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41375-020-0880-3","article-title":"Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice","volume":"35","author":"Ozono","year":"2021","journal-title":"Leukemia"},{"issue":"22","key":"2022121313285875600_hem2022000340C47","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","article-title":"Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial","volume":"319","author":"Raghu","year":"2018","journal-title":"JAMA"},{"issue":"suppl 1","key":"2022121313285875600_hem2022000340C48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137265","article-title":"Duration of response to luspatercept in patients (Pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF)-updated data from the phase 2 ACE-536-MF-001 study","volume":"136","author":"Gerds","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313285875600_hem2022000340C49","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2021-150908","article-title":"Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis","volume":"138","author":"Bose","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2022121313285875600_hem2022000340C50","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1084\/jem.20160283","article-title":"Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis","volume":"213","author":"Verstovsek","year":"2016","journal-title":"J Exp Med"},{"issue":"suppl 1","key":"2022121313285875600_hem2022000340C51","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"issue":"S1","key":"2022121313285875600_hem2022000340C52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.HS9.0000561592.51072.9b","article-title":"A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: S828","volume":"3","author":"Verstovsek","year":"2019","journal-title":"HemaSphere"},{"issue":"10","key":"2022121313285875600_hem2022000340C53","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.2019000051","article-title":"Increased SLAMF7 high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab","volume":"134","author":"Maekawa","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2022121313285875600_hem2022000340C54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00277-021-04683-w","article-title":"Favorable overall survival with imetelstat in relapsed\/refractory myelofibrosis patients compared with real-world data","volume":"101","author":"Kuykendall","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"2022121313285875600_hem2022000340C55","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022121313285875600_hem2022000340C56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"11","key":"2022121313285875600_hem2022000340C57","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood.V112.11.2809.2809","article-title":"Phase II trial of low dose, subcutaneous decitabine in myelofibrosis","volume":"112","author":"Odenike","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2022121313285875600_hem2022000340C58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11899-020-00598-x","article-title":"Non-pharmacologic management of splenomegaly for patients with myelofibrosis: is there any role for splenectomy or splenic radiation in 2020?","volume":"15","author":"Sankar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2022121313285875600_hem2022000340C59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.15450","article-title":"The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib","volume":"182","author":"Cris\u00e0","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2022121313285875600_hem2022000340C60","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.12846","article-title":"Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis","volume":"98","author":"Hern\u00e1ndez-Boluda","year":"2017","journal-title":"Eur J Haematol"},{"issue":"12","key":"2022121313285875600_hem2022000340C61","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1080\/1042819021000040008","article-title":"Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies","volume":"43","author":"Barosi","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2022121313285875600_hem2022000340C62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2004.08.160","article-title":"Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial","volume":"22","author":"Marchetti","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"2022121313285875600_hem2022000340C63","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","article-title":"Lenalidomide therapy in myelofibrosis with myeloid metaplasia","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2022121313285875600_hem2022000340C64","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2016.300","article-title":"A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"2022121313285875600_hem2022000340C65","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","article-title":"Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results","volume":"94","author":"Cervantes","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"2022121313285875600_hem2022000340C66","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.3324\/haematol.2020.260125","article-title":"The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis","volume":"106","author":"Shoukier","year":"2021","journal-title":"Haematologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/235\/2022977\/235reynolds.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/235\/2022977\/235reynolds.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:32:28Z","timestamp":1670938348000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/235\/493507\/New-approaches-to-tackle-cytopenic-myelofibrosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000340","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}